La información proporcionada en EL7.AI es solo con fines educativos e informativos y no constituye asesoramiento financiero.
La información proporcionada en EL7.AI es solo con fines educativos e informativos y no constituye asesoramiento financiero.
Rhythm Pharmaceuticals' shares dropped after its experimental drug for genetic obesity failed to meet the primary goal of its late-stage clinical trial. Meanwhile, rival drugs achieved strong weight loss results, prompting Roche to re-enter the obesity market. Additionally, Novo Nordisk's patent expiry paves the way for cheaper weight-loss drugs in India.